DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20171101

Adverse drug reaction to antiparkinson agents in Idiopathic Parkinson Disease: a prospective observational study in a Movement Disorder outpatient clinic

Firoz Thaha, Reneega Gangadhar, Thomas Iype, Reeja Rajan

Abstract


Background: Parkinson disease (PD) generally requires therapy for prolonged periods often with multiple drugs; drug-related adverse effects often add to the existing morbidity. Although, such ADRs are common, comprehensive information about their incidence, severity, and ultimate health effects are not available. The objective of the study was to analyze the pattern of occurrence of Adverse Drug Reactions (ADRs) in patients receiving anti-parkinson agents (APA) in a tertiary care hospital. We also aimed to assess the causality, severity and preventability of these ADRs.

Methods: This prospective, observational study with 6 month follow up was conducted among consecutive PD patients receiving anti parkinson agents attending the Movement disorder clinic of Neurology department between April 1st 2011 and September 30th 2012. Tools used were ADR Reporting form of National Pharmacovigilance centre, WHO causality scale, Hartwig and Siegel scale to assess severity and Schumock and Thornton scale to assess preventability of ADRs. Descriptive statistics was used and the values were expressed in numbers and percentages.

Results: ADRs were experienced in 87 patients (82.1%) out of 106 patients and most of these patients were on combination therapy (66%). No gender difference in distribution of ADRs was observed. The most common reactions were sedation, dizziness, dry mouth and fatigue. The drug usage was in the order of pramipexole (58.4%), levodopa+carbidopa (55.7%), trihexyphenidyl (28.3%), entacapone (5.7%) and amantadine (7.5%). Majority of the ADRs were mild level 1 (71.1%). ADR was maximum with entacapone. Majority of ADRs belonged to the causality possible ADR category. All the ADRs came under the definitely or probably preventable category.

Conclusions: ADRs with antiparkinsonian drugs is common but mild and preventable.


Keywords


Adverse drug event, Causality, Observational study, Patient harm, Prospective studies

Full Text:

PDF

References


Okubadejo NU, Ojo OO, Oshinaike OO. Clinical profile of parkinsonism and Parkinson's disease in Lagos, Southwestern Nigeria. BMC Neurology. 2010;10(1):1.

Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rüb U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). Journal of Neurology. 2002;249(3):iii1-5.

Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of aging. 2003;24(2):197-211.

Kostic V, Przedborski S, Flaster E, Sternic N. Early development of levodopa‐induced dyskinesias and response fluctuations in young‐onset Parkinson's disease. Neurology. 1991;41(2 Part 1):202-5.

Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA. 2000;284(15):1931-8.

Olivier R, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five–year study of the incidence of dyskinesia in patients with early parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342:1484-91.

Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61(7):1044-53.

Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ. 1995;311(7020):1602-7.

Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Archives of neurology. 2005;62(6):905-10.

Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA. 1997;277(4):301-6.

Nerurkar RP, Nadkar MY, Bichile SK. Need for monitoring adverse drug reactions. J Assoc Physicians India. 1998;46:673-4.

Bavdekar, Sandeep B. Monitoring adverse drug events: need for an active surveillance system. Indian pediatrics. 2004;41(8):860-0.

Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. Journal of Neurology, Neurosurgery and Psychiatry. 1992;55(3):181-4.

Zaki SA. ADR and causality assessment scales. Lung India: Official Organ of Indian Chest Society. 2011;28(2):152-3.

Schumock G, Thornton J. Focusing on the preventability of ADRs. Hospital Pharmacy. 1992;27(6):538.

Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting ADRs. American Journal of Health-System Pharmacy. 1992;49(9):2229-32.

Perez‐Lloret S, Bondon‐Guitton E, Rascol O, Montastruc JL. Adverse drug reactions to dopamine agonists: A comparative study in the French Pharmacovigilance Database. Movement Disorders. 2010;25(12):1876-80.

Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE. Levodopa-dyskinesia incidence by age of Parkinson's disease onset. Movement Disorders. 2005;20(3):342-4.

Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA. 2002;287(4):455-63.

Mandal A, Chatterjee S, Das SK, Mishra A. Drug safety monitoring in patients of movement disorders of a tertiary care hospital. Indian J Pharmacol. 2010;42:249-51.

Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson’s disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry. 1999;66:436-41.

Parkes JD, Baxter RC, Marsden CD, Rees JE. Comparative trial of benzhexol, amantadine, and levodopa in the treatment of parkinson’s disease. Journal of Neurology, Neurosurgery, and Psychiatry. 1974;37:422-6.

Dallos V, Stone P, Heathfield K, Allen F. The comparative value of amantadine and levodopa. Postgraduate Medical Journal. 1972;48:354-8.

Brooks DJ, Sagar H. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry. 2003;74:1071-9.

Price PA, Parkes JD, Marsden CD. Sodium valproate in the treatment of levodopa-induced dyskinesia. Journal of Neurology, Neurosurgery, and Psychiatry. 1978;41:702-6.

Thanvi B, Lo N, Robinson T. Levodopa-induced dyskinesia in parkinson’s disease: clinical features, pathogenesis, prevention and treatment. Postgrad Med J. 2007;83:384-8.

Pintor L, Valldeoriola F, Bailles E, Marti MJ, Muniz A, Tolosa E. Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial. Clin Neuropharmacol. 2012;35(2):61-6.

Horrocks PM, Vicary DJ, Rees JE, Parkes JD, Marsden CD. Anticholinergic withdrawal and benzhexol treatment in parkinson’s disease. Journal of Neurology, Neurosurgery, and Psychiatry. 1973;36:936-41.